Assembly Biosciences (ASMB) |
|
4.48 -0.15 (-3.24%)
|
03-07 04:43 |
|
Open: |
4.64 |
Pre. Close: |
4.63 |
|
High:
|
4.66 |
Low:
|
4.305 |
|
Volume:
|
2,599,252 |
Market Cap:
|
171M |
|
|
|
|
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.69 - 4.735 |
4.735 - 4.763 |
|
Low:
|
4.209 - 4.265 |
4.265 - 4.299 |
|
Close:
|
4.414 - 4.508 |
4.508 - 4.564 |
|
Technical analysis |
as of: 2021-03-05 5:05:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.99  One year: 8.20 |
| Support: |
Support1: 4.30 Support2: 3.58 |
| Resistance: |
Resistance1: 5.98 Resistance2: 7.02 |
| Pivot: |
5.44 |
| Moving Average: |
MA(5): 4.81 MA(20): 5.69
MA(100): 7.63 MA(250): 14.68 |
| MACD: |
MACD(12,26): -0.37 Signal(9): -0.24 |
| Stochastic oscillator: |
%K(14,3): 4.54  %D(3): 2.69 |
| RSI: |
RSI(14): 21.94 |
| 52-week: |
High: 27.84 Low: 4.30 Change(%): -74.4 |
| Average Vol(K): |
3-Month: 127645 10-Days: 213207 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ASMB has closed above bottom band by 5.7%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 05 Mar 2021
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Thu, 04 Mar 2021
Truist Securiti Comments on Assembly Biosciences, Inc.'s FY2021 Earnings (NASDAQ:ASMB) - MarketBeat
Sun, 28 Feb 2021
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript - Seeking Alpha
Sun, 28 Feb 2021
Assembly Biosciences (ASMB) Receives a Buy from Robert W. Baird - Analyst Ratings
Fri, 26 Feb 2021
Is Assembly Biosciences Inc (ASMB) Stock Worth a Buy Friday? - InvestorsObserver
Thu, 25 Feb 2021
Assembly Biosciences: 4Q Earnings Snapshot - San Francisco Chronicle
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
33 |
| Shares Float (M) |
25 |
|
% Held by Insiders
|
4.65 |
|
% Held by Institutions
|
94.26 |
|
Shares Short (K)
|
2,600 |
|
Shares Short P. Month (K)
|
2,990 |
Stock Financials |
|
EPS
|
-1.490 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
8.220 |
|
Profit Margin
|
-60.14 |
|
Operating Margin
|
-62.92 |
|
Return on Assets (ttm)
|
-12.3 |
|
Return on Equity (ttm)
|
-23.3 |
|
Qtrly Rev. Growth
|
718.0 |
|
Gross Profit (p.s.)
|
-2.114 |
|
Sales Per Share
|
2.508 |
|
EBITDA (p.s.)
|
-1.563 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-58 |
|
Levered Free Cash Flow (M)
|
-13 |
Stock Valuations |
|
PE Ratio
|
-3.01 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.55 |
|
Price to Sales
|
1.78 |
|
Price to Cash Flow
|
-2.54 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
